PMID- 31711197
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2041-2657 (Electronic)
IS  - 2041-2649 (Print)
IS  - 2041-2649 (Linking)
VI  - 19
IP  - 3
DP  - 2020 May 20
TI  - CRISPR therapy towards an HIV cure.
PG  - 201-208
LID - 10.1093/bfgp/elz021 [doi]
AB  - Tools based on RNA interference (RNAi) and the recently developed clustered 
      regularly short palindromic repeats (CRISPR) system enable the selective 
      modification of gene expression, which also makes them attractive therapeutic 
      reagents for combating HIV infection and other infectious diseases. Several 
      parallels can be drawn between the RNAi and CRISPR-Cas9 platforms. An ideal RNAi 
      or CRISPR-Cas9 therapeutic strategy for treating infectious or genetic diseases 
      should exhibit potency, high specificity and safety. However, therapeutic 
      applications of RNAi and CRISPR-Cas9 have been challenged by several major 
      limitations, some of which can be overcome by optimal design of the therapy or 
      the design of improved reagents. In this review, we will discuss some advantages 
      and limitations of anti-HIV strategies based on RNAi and CRISPR-Cas9 with a focus 
      on the efficiency, specificity, off-target effects and delivery methods.
CI  - (c) The Author(s) 2019. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Herrera-Carrillo, Elena
AU  - Herrera-Carrillo E
AD  - Department of Medical Microbiology Laboratory of Experimental Virology Amsterdam 
      UMC, AMC, University of Amsterdam, Amsterdam, the Netherlands.
FAU - Gao, Zongliang
AU  - Gao Z
AD  - Department of Medical Microbiology Laboratory of Experimental Virology Amsterdam 
      UMC, AMC, University of Amsterdam, Amsterdam, the Netherlands.
FAU - Berkhout, Ben
AU  - Berkhout B
AD  - Department of Medical Microbiology Laboratory of Experimental Virology Amsterdam 
      UMC, AMC, University of Amsterdam, Amsterdam, the Netherlands.
AD  - Department of Life and Environmental Sciences, University of Cagliari, Cagliari, 
      Italy.
LA  - eng
GR  - R01 AI145045/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Brief Funct Genomics
JT  - Briefings in functional genomics
JID - 101528229
SB  - IM
MH  - Clustered Regularly Interspaced Short Palindromic Repeats/*genetics
MH  - Gene Editing/*methods
MH  - Genetic Therapy/methods
MH  - HIV Infections/*genetics
MH  - Humans
MH  - Lentivirus/genetics
PMC - PMC7239311
OTO - NOTNLM
OT  - CRISPR-Cas
OT  - HIV
OT  - RNA interference
OT  - gene therapy
OT  - lentiviral vector
OT  - polymerase III promoter
EDAT- 2019/11/12 06:00
MHDA- 2021/07/20 06:00
PMCR- 2020/11/08
CRDT- 2019/11/12 06:00
PHST- 2019/06/19 00:00 [received]
PHST- 2019/08/19 00:00 [revised]
PHST- 2019/08/21 00:00 [accepted]
PHST- 2019/11/12 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2019/11/12 06:00 [entrez]
PHST- 2020/11/08 00:00 [pmc-release]
AID - 5614853 [pii]
AID - elz021 [pii]
AID - 10.1093/bfgp/elz021 [doi]
PST - ppublish
SO  - Brief Funct Genomics. 2020 May 20;19(3):201-208. doi: 10.1093/bfgp/elz021.